<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01892709</url>
  </required_header>
  <id_info>
    <org_study_id>MMC 12-12-408</org_study_id>
    <nct_id>NCT01892709</nct_id>
  </id_info>
  <brief_title>Titration of Intravenous Hydromorphone</brief_title>
  <official_title>Efficacy of an Acute Pain Titration Protocol Driven by Patient Response to a Simple Query: Do You Want More Pain Medication?</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Montefiore Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Montefiore Medical Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is an exploratory, hypothesis-generating safety and efficacy study for patients who come
      to the ER in acute (less than 7 days in duration) severe pain. Patients with chronic pain
      will not be enrolled. Eligible patients will receive up to a maximum of 4 mg IV hydromorphone
      over a 4 hour period. Hydromorphone will be given as 1 mg increments based on how the patient
      responds to the question, &quot;Do you want more pain medicine?&quot;. This question will be asked
      repeatedly 30 minutes after the patient answers &quot;no&quot; or 30 minutes after the most recent dose
      of IV hydromorphone (which occurs if the patient answers &quot;yes&quot;). Up to 10% (approximately 30
      patients) will serve as a pilot at the start of the study.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>June 2013</start_date>
  <completion_date type="Actual">April 2014</completion_date>
  <primary_completion_date type="Actual">April 2014</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants Requesting Pain Medication in Different Patterns Over Time</measure>
    <time_frame>4 hours</time_frame>
    <description>This is a descriptive hypothesis-generating trial, which is why it is not being compared in a randomized fashion to a comparison group. We are examining extended titration by expanding our &quot;1+1&quot; protocol to a &quot;1+1+1+1&quot; protocol and the various patterns of opioid request. For example, some may state &quot;no&quot; every time they are asked &quot;Do you want more pain medication?&quot; Some will state &quot;yes&quot; each time, and others will answer &quot;yes&quot; and &quot;no&quot; at different time periods. We will report these various patterns (i.e. X participants answered &quot;no&quot; everytime they were asked, Y answered &quot;yes&quot; everytime they were asked, Z answered &quot;no&quot; twice, etc).
Time points 2, 3, and 4 are dependent on patient response to &quot;Do you want more pain medication?&quot; Time 1 is 30 min post-baseline. For those who answer &quot;no&quot;, Time 2 is 30 minutes later (at 1 hour), and for yes, Time 2 is 30 minutes after additional pain medication is given. This pattern follows for Time 3 and 4, with a total study time of 4 hours</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Adverse Events and Side Effects by Total Amount of Hydromorphone Received</measure>
    <time_frame>120 min</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">215</enrollment>
  <condition>Acute Severe Pain</condition>
  <arm_group>
    <arm_group_label>Hydromorphone</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>All eligible patients will receive 1 mg IV hydromorphone. Thereafter, they will be repeatedly asked the question, &quot;Do you want more pain medicine?&quot; This question will be asked 30 minutes after they answered &quot;no&quot; or 30 minutes after the completion of the next dose of 1 mg IV hydromorphone, which occurs when the patients answers &quot;yes&quot;. Patients will receive a maximum of 4 mg IV hydromorphone over a 4 hour period.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Hydromorphone</intervention_name>
    <arm_group_label>Hydromorphone</arm_group_label>
    <other_name>Dilaudid</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  1. Age greater than 21 years: Patients under the age of 21 are automatically triaged
             to the Children's Hospital at Montefiore Emergency Department, and hence cannot be
             enrolled in this study.

             2. Age less than 65 years: Patients age 65 and over will be excluded from this study
             as the effects on opioids on the elderly may be different than in the non-elderly.

             3. Pain with onset within 7 days: Pain within seven days is the definition of acute
             pain that has been used in Emergency Department (ED) literature.

             4. ED attending physician's judgment that patient's pain warrants use of morphine

             5. Normal mental status: In order to provide measures of pain experienced the patient
             needs to have a normal mental status. Orientation to person, place and time will be
             used as an indicator of sufficiently normal mental status to participate in the study.

        Exclusion Criteria:

          -  1. Prior use of methadone: the effect of methadone use on the perception of acute pain
             is unknown and suspected to be altered. Similar to sickle cell patients and chronic
             cancer patients, patients on methadone usually require significantly higher doses of
             opioids to control their pain.

             2. Use of other opioids or tramadol within past 24 hours: to avoid introducing bias
             related to opioid tolerance that may alter the response to the study medication
             thereby masking the medication's effect.

             3. Prior adverse reaction to hydromorphone: patients will be excluded if they state
             that they have an allergy to hydromorphone.

             4. Chronic pain syndrome: frequently recurrent or daily pain for at least 3 months
             result in alteration in pain perception which is thought to be due to down-regulation
             of pain receptors. Examples of chronic pain syndromes include sickle cell anemia,
             osteoarthritis, fibromyalgia, migraine, and peripheral neuropathies.

             5. Patients for whom the attending physician suspects is addicted to opioids: patients
             will be excluded if the attending suspects the patient may be addicted to opioids or
             seeking to obtain them for diversionary reasons, such as for monetary profit or other
             illicit use.

             6. Alcohol intoxication: the presence of alcohol intoxication as judged by the
             treating physician may alter perception, report, and treatment of pain.

             7. Systolic Blood Pressure &lt;100 mm Hg: Hydromorphone can produce peripheral
             vasodilation that may result in orthostatic hypotension or syncope.

             8. Respiratory rate &lt; 12/minute: Hydromorphone can cause respiratory depression.

             9. Oxygen saturation &lt;95% on room air: For this study, oxygen saturation must be 95%
             or above on room air in order to be enrolled.

             10. Heart rate &lt; 60 beats/minute: Hydromorphone can cause bradycardia.

             11. Use of monoamine oxidase (MAO) inhibitors in past 30 days: MAOs have been reported
             to intensify the effects of at least one opioid drug causing anxiety, confusion and
             significant respiratory depression or coma.

             12. Carbon dioxide measurement greater than 46: three subsets of patients will have
             their carbon dioxide measured using a handheld capnometer prior to enrollment in the
             study. If the carbon dioxide measurement is greater than 46, then the patient will be
             excluded from the study. The 3 subsets are as follows:

               1. All patients who have a history of chronic obstructive pulmonary disease (COPD)

               2. All patients who report a history of asthma together with greater than a 20
                  pack-year smoking history

               3. All patients reporting less than a 20 pack-year smoking history who are having an
                  asthma exacerbation
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>64 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Andrew K Chang, MD, MS</last_name>
    <role>Principal Investigator</role>
    <affiliation>Montefiore Medical Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Montefiore Medical Center Moses Emegency Department</name>
      <address>
        <city>Bronx</city>
        <state>New York</state>
        <zip>10467</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 6, 2013</study_first_submitted>
  <study_first_submitted_qc>July 1, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 4, 2013</study_first_posted>
  <results_first_submitted>February 16, 2018</results_first_submitted>
  <results_first_submitted_qc>April 20, 2018</results_first_submitted_qc>
  <results_first_posted type="Actual">April 24, 2018</results_first_posted>
  <last_update_submitted>April 20, 2018</last_update_submitted>
  <last_update_submitted_qc>April 20, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">April 24, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Montefiore Medical Center</investigator_affiliation>
    <investigator_full_name>Andrew Chang, MD</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>acute</keyword>
  <keyword>pain</keyword>
  <keyword>emergency department</keyword>
  <keyword>hydromorphone</keyword>
  <keyword>in ER</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hydromorphone</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Hydromorphone</title>
          <description>All eligible patients will receive 1 mg IV hydromorphone. Thereafter, they will be repeatedly asked the question, &quot;Do you want more pain medicine?&quot; This question will be asked 30 minutes after they answered &quot;no&quot; or 30 minutes after the completion of the next dose of 1 mg IV hydromorphone, which occurs when the patients answers &quot;yes&quot;. Patients will receive a maximum of 4 mg IV hydromorphone over a 4 hour period.
Hydromorphone</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="215"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="215"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>8 patients excluded from initial 215 for protocol violations: 1 from missing data, 7 for failure to receive intravenous hydromorphone after requesting it</population>
      <group_list>
        <group group_id="B1">
          <title>Hydromorphone</title>
          <description>All eligible patients will receive 1 mg IV hydromorphone. Thereafter, they will be repeatedly asked the question, &quot;Do you want more pain medicine?&quot; This question will be asked 30 minutes after they answered &quot;no&quot; or 30 minutes after the completion of the next dose of 1 mg IV hydromorphone, which occurs when the patients answers &quot;yes&quot;. Patients will receive a maximum of 4 mg IV hydromorphone over a 4 hour period.
Hydromorphone</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="207"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="41" spread="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="122"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="85"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>Hispanic</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="143"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Black</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="44"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>White/Other</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="207"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Weight</title>
          <units>lbs</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="177" spread="34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Location of pain</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>Abdomen/pelvis</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="153"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Flank</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Back</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Extremities</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Other</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Initial NRS pain intensity</title>
          <description>Pain intensity is measured on the numerical rating scale (NRS) from 0 (&quot;no pain&quot;) to 10 (&quot;worst pain imaginable&quot;)</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>NRS = 5-7</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>NRS = 8</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>NRS = 9</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="41"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>NRS = 10</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="118"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Nauseated or vomited before receiving first dose of opioid</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="134"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants Requesting Pain Medication in Different Patterns Over Time</title>
        <description>This is a descriptive hypothesis-generating trial, which is why it is not being compared in a randomized fashion to a comparison group. We are examining extended titration by expanding our &quot;1+1&quot; protocol to a &quot;1+1+1+1&quot; protocol and the various patterns of opioid request. For example, some may state &quot;no&quot; every time they are asked &quot;Do you want more pain medication?&quot; Some will state &quot;yes&quot; each time, and others will answer &quot;yes&quot; and &quot;no&quot; at different time periods. We will report these various patterns (i.e. X participants answered &quot;no&quot; everytime they were asked, Y answered &quot;yes&quot; everytime they were asked, Z answered &quot;no&quot; twice, etc).
Time points 2, 3, and 4 are dependent on patient response to &quot;Do you want more pain medication?&quot; Time 1 is 30 min post-baseline. For those who answer &quot;no&quot;, Time 2 is 30 minutes later (at 1 hour), and for yes, Time 2 is 30 minutes after additional pain medication is given. This pattern follows for Time 3 and 4, with a total study time of 4 hours</description>
        <time_frame>4 hours</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Hydromorphone</title>
            <description>All eligible patients will receive 1 mg IV hydromorphone. Thereafter, they will be repeatedly asked the question, &quot;Do you want more pain medicine?&quot; This question will be asked 30 minutes after they answered &quot;no&quot; or 30 minutes after the completion of the next dose of 1 mg IV hydromorphone, which occurs when the patients answers &quot;yes&quot;. Patients will receive a maximum of 4 mg IV hydromorphone over a 4 hour period.
Hydromorphone</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Requesting Pain Medication in Different Patterns Over Time</title>
          <description>This is a descriptive hypothesis-generating trial, which is why it is not being compared in a randomized fashion to a comparison group. We are examining extended titration by expanding our &quot;1+1&quot; protocol to a &quot;1+1+1+1&quot; protocol and the various patterns of opioid request. For example, some may state &quot;no&quot; every time they are asked &quot;Do you want more pain medication?&quot; Some will state &quot;yes&quot; each time, and others will answer &quot;yes&quot; and &quot;no&quot; at different time periods. We will report these various patterns (i.e. X participants answered &quot;no&quot; everytime they were asked, Y answered &quot;yes&quot; everytime they were asked, Z answered &quot;no&quot; twice, etc).
Time points 2, 3, and 4 are dependent on patient response to &quot;Do you want more pain medication?&quot; Time 1 is 30 min post-baseline. For those who answer &quot;no&quot;, Time 2 is 30 minutes later (at 1 hour), and for yes, Time 2 is 30 minutes after additional pain medication is given. This pattern follows for Time 3 and 4, with a total study time of 4 hours</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="207"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>No requests for additional pain medication</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="94"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Requested additional pain medication, Time 1 only</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Requested additional pain medication, Time 2 only</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Requested additional pain medication, Time 3 only</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Requested additional pain medication, Time 4 only</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Requested add'l pain medication at &gt;1 time point</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Adverse Events and Side Effects by Total Amount of Hydromorphone Received</title>
        <time_frame>120 min</time_frame>
        <population>Nausea and vomiting were only assessed as adverse events among patients who did not have nausea and vomiting before the study began</population>
        <group_list>
          <group group_id="O1">
            <title>1 mg Hydromorphone</title>
            <description>Received 1 mg of IV hydromorphone, and answered &quot;no&quot; to all repeated questions of &quot;Do you want more pain medication?&quot;</description>
          </group>
          <group group_id="O2">
            <title>2 mg Hydromorphone</title>
            <description>Received 2 mg of IV hydromorphone, in 2 1-mg doses.</description>
          </group>
          <group group_id="O3">
            <title>3 mg Hydromorphone</title>
            <description>Received 3 mg of IV hydromorphone, in 3 1-mg doses</description>
          </group>
          <group group_id="O4">
            <title>4 mg Hydromorphone</title>
            <description>Received 4 mg of IV hydromorphone, in 4 1-mg doses</description>
          </group>
        </group_list>
        <measure>
          <title>Adverse Events and Side Effects by Total Amount of Hydromorphone Received</title>
          <population>Nausea and vomiting were only assessed as adverse events among patients who did not have nausea and vomiting before the study began</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="114"/>
                <count group_id="O2" value="78"/>
                <count group_id="O3" value="9"/>
                <count group_id="O4" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Oxygen saturation &lt;95%</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="114"/>
                    <count group_id="O2" value="78"/>
                    <count group_id="O3" value="9"/>
                    <count group_id="O4" value="6"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="5"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Respiratory Rate &lt;10 breaths/min</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="114"/>
                    <count group_id="O2" value="78"/>
                    <count group_id="O3" value="9"/>
                    <count group_id="O4" value="6"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pulse rate &lt;50 beats/min</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="114"/>
                    <count group_id="O2" value="78"/>
                    <count group_id="O3" value="9"/>
                    <count group_id="O4" value="6"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Systolic blood pressure &lt;90 mmHg</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="114"/>
                    <count group_id="O2" value="78"/>
                    <count group_id="O3" value="9"/>
                    <count group_id="O4" value="6"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pruritus</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="114"/>
                    <count group_id="O2" value="78"/>
                    <count group_id="O3" value="9"/>
                    <count group_id="O4" value="6"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                    <measurement group_id="O2" value="8"/>
                    <measurement group_id="O3" value="2"/>
                    <measurement group_id="O4" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Nausea</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="28"/>
                    <count group_id="O2" value="26"/>
                    <count group_id="O3" value="2"/>
                    <count group_id="O4" value="4"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="14"/>
                    <measurement group_id="O3" value="2"/>
                    <measurement group_id="O4" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Vomiting</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="28"/>
                    <count group_id="O2" value="26"/>
                    <count group_id="O3" value="2"/>
                    <count group_id="O4" value="4"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="5"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Post-Hoc</type>
        <title>Number of Patients Responding to the Question, &quot;Do You Want More Pain Medication?&quot; at Each Time Point</title>
        <description>Time points 2, 3, and 4 are dependent on patient response to &quot;Do you want more pain medication?&quot; Time 1 is 30 min post-baseline. For those who answer &quot;no&quot; at Time 1, Time 2 is 30 minutes later (at 1 hour), and for those who answer yes, Time 2 is 30 minutes after additional pain medication is given. This pattern follows for Time 3 and 4, with a total study time of 4 hours</description>
        <time_frame>4 hours</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Hydromorphone</title>
            <description>All eligible patients will receive 1 mg IV hydromorphone. Thereafter, they will be repeatedly asked the question, &quot;Do you want more pain medicine?&quot; This question will be asked 30 minutes after they answered &quot;no&quot; or 30 minutes after the completion of the next dose of 1 mg IV hydromorphone, which occurs when the patients answers &quot;yes&quot;. Patients will receive a maximum of 4 mg IV hydromorphone over a 4 hour period.
Hydromorphone</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Patients Responding to the Question, &quot;Do You Want More Pain Medication?&quot; at Each Time Point</title>
          <description>Time points 2, 3, and 4 are dependent on patient response to &quot;Do you want more pain medication?&quot; Time 1 is 30 min post-baseline. For those who answer &quot;no&quot; at Time 1, Time 2 is 30 minutes later (at 1 hour), and for those who answer yes, Time 2 is 30 minutes after additional pain medication is given. This pattern follows for Time 3 and 4, with a total study time of 4 hours</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="207"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Time 1</title>
              <category_list>
                <category>
                  <title>Yes</title>
                  <measurement_list>
                    <measurement group_id="O1" value="42"/>
                  </measurement_list>
                </category>
                <category>
                  <title>No</title>
                  <measurement_list>
                    <measurement group_id="O1" value="165"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Time 2</title>
              <category_list>
                <category>
                  <title>Yes</title>
                  <measurement_list>
                    <measurement group_id="O1" value="41"/>
                  </measurement_list>
                </category>
                <category>
                  <title>No</title>
                  <measurement_list>
                    <measurement group_id="O1" value="166"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Time 3</title>
              <category_list>
                <category>
                  <title>Yes</title>
                  <measurement_list>
                    <measurement group_id="O1" value="31"/>
                  </measurement_list>
                </category>
                <category>
                  <title>No</title>
                  <measurement_list>
                    <measurement group_id="O1" value="176"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Time 4</title>
              <category_list>
                <category>
                  <title>Yes</title>
                  <measurement_list>
                    <measurement group_id="O1" value="39"/>
                  </measurement_list>
                </category>
                <category>
                  <title>No</title>
                  <measurement_list>
                    <measurement group_id="O1" value="168"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Post-Hoc</type>
        <title>Mean Pain Intensity Score in Numerical Rating Scale (NRS) Units at Each Time Point, Based on Response to the Question, &quot;Do You Want More Pain Medication?&quot;</title>
        <description>Pain intensity is measured on the numerical rating scale (NRS) with scores from 0 (&quot;no pain&quot;) to 10 (&quot;worst pain imaginable&quot;).
Time points 2, 3, and 4 are dependent on patient response to &quot;Do you want more pain medication?&quot; Time 1 is 30 min post-baseline. For those who answer &quot;no&quot; at Time 1, Time 2 is 30 minutes later (at 1 hour), and for those who answer yes, Time 2 is 30 minutes after additional pain medication is given. This pattern follows for Time 3 and 4, with a total study time of 4 hours</description>
        <time_frame>4 hours</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Hydromorphone</title>
            <description>All eligible patients will receive 1 mg IV hydromorphone. Thereafter, they will be repeatedly asked the question, &quot;Do you want more pain medicine?&quot; This question will be asked 30 minutes after they answered &quot;no&quot; or 30 minutes after the completion of the next dose of 1 mg IV hydromorphone, which occurs when the patients answers &quot;yes&quot;. Patients will receive a maximum of 4 mg IV hydromorphone over a 4 hour period.
Hydromorphone</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Pain Intensity Score in Numerical Rating Scale (NRS) Units at Each Time Point, Based on Response to the Question, &quot;Do You Want More Pain Medication?&quot;</title>
          <description>Pain intensity is measured on the numerical rating scale (NRS) with scores from 0 (&quot;no pain&quot;) to 10 (&quot;worst pain imaginable&quot;).
Time points 2, 3, and 4 are dependent on patient response to &quot;Do you want more pain medication?&quot; Time 1 is 30 min post-baseline. For those who answer &quot;no&quot; at Time 1, Time 2 is 30 minutes later (at 1 hour), and for those who answer yes, Time 2 is 30 minutes after additional pain medication is given. This pattern follows for Time 3 and 4, with a total study time of 4 hours</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="207"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Time 1, Yes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.4" lower_limit="3" upper_limit="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Time 1, No</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.8" lower_limit="0" upper_limit="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Time 2, Yes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.2" lower_limit="4" upper_limit="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Time 2, No</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.9" lower_limit="0" upper_limit="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Time 3, Yes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.1" lower_limit="3" upper_limit="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Time 3, No</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.1" lower_limit="0" upper_limit="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Time 4, Yes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.8" lower_limit="0" upper_limit="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Time 4, No</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.4" lower_limit="0" upper_limit="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>120 minutes</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Hydromorphone</title>
          <description>All eligible patients will receive 1 mg IV hydromorphone. Thereafter, they will be repeatedly asked the question, &quot;Do you want more pain medicine?&quot; This question will be asked 30 minutes after they answered &quot;no&quot; or 30 minutes after the completion of the next dose of 1 mg IV hydromorphone, which occurs when the patients answers &quot;yes&quot;. Patients will receive a maximum of 4 mg IV hydromorphone over a 4 hour period.
Hydromorphone</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="207"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="207"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="68" subjects_at_risk="207"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Nausea</sub_title>
                <description>excluding patients who had nausea or vomiting before the study began</description>
                <counts group_id="E1" subjects_affected="25" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <description>excluding patients who had nausea or vomiting before the study began</description>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="60"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Oxygen saturation &lt;95%</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="207"/>
              </event>
              <event>
                <sub_title>Respiratory rate &lt; 10 breaths/min</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="207"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Pruritus</sub_title>
                <counts group_id="E1" subjects_affected="20" subjects_at_risk="207"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Pulse rate &lt; 50 beats/min</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="207"/>
              </event>
              <event>
                <sub_title>Systolic blood pressure &lt; 90 mmHg</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="207"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Andrew Chang, MD, MS</name_or_title>
      <organization>Department of Emergency Medicine, Albert Einstein College of Medicine, Montefiore Medical Center</organization>
      <phone>718-920-7476</phone>
      <email>achang@montefiore.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

